TEL AVIV, Israel and BETHESDA, Maryland, Jan. 31, 2019 /PRNewswire/ — Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced that it has filed an additional four provisional patent applications with the Israel Patent Office, for cannabinoid-based drugs and treatments, designed for conditions associated with non-epileptic seizures and tremors.
Dr. Eyal Ballan and Eyal Barad, co-founders of Cannabics, believe that the company’s clinical experience and personalization platform may allow for personalized cannabinoid solutions for conditions and syndromes such as Alcohol Withdrawal Syndrome (AWS), REM related sleep disorder (RBD), Psychogenic non-epileptic seizures (PNES) and Drug-induced tremors, found as extrapyramidal side effects (EPSE).
The patent protection of new disease specific and patient specific cannabinoid compositions and treatment protocols has already begun, with these four patent applications filed this month alone, with several and more in progress.
Dr. Eyal Ballan, CTO and Co-Founder, said: “Cannabics is broadening its potential offerings to the healthcare industry. We believe that the company’s expertise in clinical evaluation of cannabinoid formulations has now been brought to bear in designing specific drugs and treatments which will potentially benefit many patients globally.”
About Cannabics Pharmaceuticals
Cannabics Pharmaceuticals Inc. (CNBX) is a U.S-based public company that is developing a platform which leverages novel drug-screening tools and artificial intelligence to create cannabinoid-based therapies for cancer that are more suitable to a patient’s profile. By developing tools to assess effectiveness on a personalized basis, Cannabics is helping to move cannabinoids into the future of cancer therapy. The company’s R&D is based in Israel, where it is licensed by the Ministry of Health to conduct scientific and clinical research on cannabinoid formulations and Cancer.
For the latest updates on Cannabics Pharmaceuticals follow the company on Twitter @cannabics1, Facebook @CannabicsPharmaceuticals, LinkedIn, and on Instagram: @Cannabics_Pharmaceuticals.
Disclaimer:
Certain statements contained in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include but are not limited to statements identified by words such as “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “targets,” “projects” and similar expressions. For example, we are using forward-looking statements when we discuss the belief that our clinical experience and personalization platform may allow for personalized cannabinoid solutions for conditions and syndromes such as Alcohol Withdrawal Syndrome (AWS), REM related sleep disorder (RBD), Psychogenic non-epileptic seizures (PNES) and Drug-induced tremors, found as extrapyramidal side effects (EPSE), the potential for the filing of new patent applications, and the belief that our expertise in clinical evaluation of cannabinoid formulations has now been brought to bear in designing specific drugs and treatments which will potentially benefit many patients globally. The statements in this release are based upon the current beliefs and expectations of our company’s management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, results of clinical trials and/or other studies, the challenges inherent in new product development initiatives, the effect of any competitive products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and/or regulation, potential litigation by or against us, any governmental review of our products or practices, as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission. We undertake no duty to update any forward-looking statement or any information contained in this press release or in other public disclosures at any time. Finally, the investing public is reminded that the only announcements or information about Cannabics Pharmaceuticals Inc. which are condoned by the Company must emanate from the Company itself and bear our name as its source.
